AttendMe Owl Logo
AttendMe
Evidence Evolution
OncologyOncology

How This Evidence Evolved

CAR-T Cell Therapy

From concept to clinical reality

10.6

Timeline

Signal

Early observations and pilot data that first suggested a new direction

CAR T-cell products studied here include autologous therapies directed at tumor antigens. TRANSCEND evaluated CD19-directed liso-cel after leukapheresis for manufacture, with CD8+ and CD4+ components given at equal target doses. ELIANA studied children and young adults with relapsed or refractory CD19-positive B-ALL: 81% of 75 infused patients had remission within three months, including incomplete hematologic recovery. Substantial toxic effects accompanied these responses.
Proof

Landmark RCTs and pivotal trials that established the evidence base

ELIANA evaluated tisagenlecleucel in pediatric and young adult patients with CD19-positive relapsed or refractory B-ALL. Among 75 infused patients, overall remission within 3 months was 81%, including complete remission with incomplete hematologic recovery. The ZUMA-1 phase 2 report enrolled 111 patients with refractory large B-cell lymphoma; 101 received axi-cel. Objective response was 82% and complete response was 54%. Both studies reported substantial toxic effects.
Extension

Follow-up studies, subgroup analyses, and real-world validation

KarMMa reported a 73% response rate in 128 ide-cel-treated patients with relapsed or refractory myeloma. CARTITUDE-1 reported ORR 97.9% and stringent complete response 82.5% at median follow-up of 27.7 months. In ZUMA-7, axi-cel improved median event-free survival to 8.3 months versus 2.0 with standard care in large B-cell lymphoma refractory to, or relapsing within 12 months after, first-line chemoimmunotherapy.
Guidelines

Integration into clinical practice guidelines and recommendations

ASTCT consensus standardized definitions and grading for CRS and neurotoxicity to improve comparability across trials and postapproval care; a grading framework does not itself establish every toxicity-management algorithm.
ASTCT Consensus Grading

Use ASTCT consensus definitions and grading for CRS and neurotoxicity.

Now

Current standard of care and ongoing research directions

Manufacturing and infusion remain distinct steps: ZUMA-1 enrolled 111 patients, manufactured axi-cel for 110 and infused 101. Future questions include whether allogeneic CAR-T can reduce delays, whether solid tumors can be treated effectively, how bispecific antibodies compare and what long-term surveillance reveals about secondary T-cell malignancies. These are distinct from a current product-approval count.

Landmark Trials in This Story

ZUMA-1 phase 22017

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

ZUMA-1 phase 2: ORR 82%; CR 54% (101 infused).

The New England journal of medicinePhase 2 single-arm trialN=111
ELIANA2018

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Remission (CR/CRi) within 3 months: 81% (75 infused).

The New England journal of medicinePhase 2 single-cohort trialN=75
TRANSCEND NHL 0012020

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Objective response in efficacy-evaluable patients: 186/256 (73%, 95% CI 66.8–78.0); complete response 136/256 (53%, 46.8–59.4).

Lancet (London, England)Multicenter seamless-design clinical trial
KarMMa2021Landmark

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Median follow-up 13.3 mo: response 73%; CR or better 33% (128 treated)

New England journal of medicineSingle-arm phase 2N=128
CARTITUDE-1 two-year follow-up2023

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.

Median follow-up 27.7 months: ORR 97.9%; sCR 82.5%.

Journal of clinical oncology : official journal of the American Society of Clinical OncologyPhase 1b/2 single-arm trialN=97
ZUMA-72022

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

Median EFS after median follow-up 24.9 months: axi-cel 8.3 vs standard care 2.0 months (HR 0.40, 95% CI 0.31 to 0.51; P<0.001).

The New England journal of medicineRCT

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

What is CAR-T cell therapy?+
The cited products are CAR T-cell therapies directed at CD19 or B-cell maturation antigen. TRANSCEND described an autologous CD19-directed product: patients underwent leukapheresis for manufacture, then received CD8+ and CD4+ CAR T-cell components at equal target doses. The trial studied patients with relapsed or refractory large B-cell lymphomas.
What cancers can be treated with CAR-T?+
Clinical trials studied pediatric/young adult relapsed or refractory B-ALL (ELIANA), refractory large B-cell lymphoma (ZUMA-1 and TRANSCEND), and heavily pretreated relapsed/refractory myeloma (KarMMa and CARTITUDE-1). These trial populations and outcomes are distinct from a complete list of current regulatory indications.
What are the main side effects of CAR-T therapy?+
CRS and neurologic events are important toxicities. ZUMA-1 reported grade ≥3 CRS in 13% and neurologic events in 28%. KarMMa reported CRS in 84% (grade ≥3 in 5%) and neurotoxicity in 18% (grade 3 in 3%). These rates concern different products and populations. ASTCT consensus defines standardized grading; differences in trial grading can limit direct comparisons.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026